James Karis

MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY.

MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY.

MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY.

MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY.

Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.

Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.

MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY.

MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY.

Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.

MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY.

MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY.

MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY.

CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward.

CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward.

CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward.

Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.

Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.

CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward.

CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward.

Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.

CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward.

Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.

Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.

Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.

Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.

CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward.

CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward.

MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY.

Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.

Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.

MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY.

MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY.

CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward.